Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve Bb-18 and Reduced Inflammation

Research synthesisLow evidenceMixed effect size4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial effects on inflammation, with effect sizes mixed (small to moderate). The highest-quality evidence (a meta-analysis of microbiome-targeted therapies) showed a small beneficial effect on inflammatory markers in type 2 diabetes. However, all studies used multi-strain products or other interventions, not Bifidobacterium breve Bb-18 alone, making direct evidence for this specific strain lacking.

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. Critically, none of the studies tested Bifidobacterium breve Bb-18 in isolation; all used multi-strain probiotics, synbiotics, or other interventions (e.g., berberine), so the specific anti-inflammatory effect of this strain is uncertain.

Generated Jul 11, 2026
4 of 4 papers
Back to top